There are no reports of pregnancy outcomes for women with PNH treated with the next-generation C5 inhibitor ravulizumab, which was approved for the treatment of PNH in 2018 [2,9]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.